Daniele, Antonio
 Distribuzione geografica
Continente #
NA - Nord America 4.558
AS - Asia 4.463
EU - Europa 4.236
SA - Sud America 1.464
AF - Africa 247
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.990
Nazione #
US - Stati Uniti d'America 4.381
SG - Singapore 2.033
BR - Brasile 1.183
IT - Italia 1.172
CN - Cina 1.142
DE - Germania 942
SE - Svezia 645
VN - Vietnam 406
IE - Irlanda 274
FR - Francia 231
ID - Indonesia 206
GB - Regno Unito 203
UA - Ucraina 171
IN - India 143
RU - Federazione Russa 142
FI - Finlandia 137
AR - Argentina 133
CI - Costa d'Avorio 113
HK - Hong Kong 88
PL - Polonia 76
MX - Messico 73
BD - Bangladesh 69
CA - Canada 66
TR - Turchia 61
IQ - Iraq 51
KR - Corea 47
AT - Austria 46
ZA - Sudafrica 44
ES - Italia 41
JP - Giappone 40
NL - Olanda 38
EC - Ecuador 36
BE - Belgio 31
CO - Colombia 30
VE - Venezuela 26
PK - Pakistan 24
AU - Australia 18
TW - Taiwan 18
PE - Perù 17
SA - Arabia Saudita 17
TN - Tunisia 16
UZ - Uzbekistan 15
MA - Marocco 14
EG - Egitto 13
JO - Giordania 13
IL - Israele 12
IR - Iran 12
KE - Kenya 12
PT - Portogallo 12
AE - Emirati Arabi Uniti 11
CL - Cile 11
PY - Paraguay 11
RO - Romania 11
UY - Uruguay 10
CZ - Repubblica Ceca 9
DO - Repubblica Dominicana 9
NP - Nepal 9
AZ - Azerbaigian 8
DZ - Algeria 8
CH - Svizzera 7
ET - Etiopia 7
AL - Albania 6
BO - Bolivia 6
GR - Grecia 6
JM - Giamaica 6
LB - Libano 6
LT - Lituania 6
HN - Honduras 5
MY - Malesia 5
SN - Senegal 5
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
HR - Croazia 4
NO - Norvegia 4
BH - Bahrain 3
DK - Danimarca 3
GT - Guatemala 3
PA - Panama 3
PH - Filippine 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
EU - Europa 2
GA - Gabon 2
KZ - Kazakistan 2
LK - Sri Lanka 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
RS - Serbia 2
SO - Somalia 2
SY - Repubblica araba siriana 2
TM - Turkmenistan 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BB - Barbados 1
BF - Burkina Faso 1
Totale 14.964
Città #
Singapore 821
Chandler 623
Ashburn 492
Beijing 260
Dublin 253
Jakarta 173
Hefei 160
Rome 132
Ho Chi Minh City 130
San Mateo 123
Wilmington 122
Abidjan 113
Jacksonville 112
Milan 111
Nanjing 108
Dallas 106
Boston 103
Dearborn 102
São Paulo 101
Los Angeles 99
Hanoi 98
Princeton 94
New York 92
Ann Arbor 90
Hong Kong 82
Moscow 78
Cattolica 66
Woodbridge 64
Redwood City 61
Fairfield 60
Warsaw 60
Frankfurt am Main 57
Helsinki 49
Seattle 49
Nürnberg 48
Houston 47
Kent 46
The Dalles 42
Munich 41
Seoul 41
Nuremberg 40
Rio de Janeiro 40
Nanchang 39
Naples 39
Chicago 38
Redmond 35
Lawrence 33
Marseille 33
Boardman 32
London 30
Guangzhou 29
Buffalo 28
Shenyang 28
Bremen 27
Izmir 27
Brooklyn 26
Curitiba 26
Norwalk 26
Brasília 25
Shanghai 25
Tokyo 25
Turku 25
Bari 24
Belo Horizonte 23
Changsha 23
Hangzhou 23
Mountain View 23
Atlanta 22
Brussels 22
Santa Clara 22
Cambridge 21
Vienna 21
Chennai 20
Kunming 20
Montreal 20
Tianjin 20
Lappeenranta 19
Campinas 18
Da Nang 18
Hebei 17
Dhaka 16
Lancaster 16
San Jose 16
Biên Hòa 15
Council Bluffs 15
Denver 15
Stockholm 15
Baghdad 14
Dong Ket 14
Düsseldorf 14
Johannesburg 14
Amman 13
Amsterdam 13
Fremont 13
Hyderabad 12
Jiaxing 12
Mexico City 12
Phoenix 12
Porto Alegre 12
Pune 12
Totale 6.836
Nome #
Neuropsichiatria dei disturbi dell’umore. In: Neuroscienze cliniche e del comportamento. Basi neurobiologiche e neuropsicologiche. Psicopatologia funzionale e neuropsichiatria A cura di C. Blundo 564
Effects of stimulation of the subthalamic nucleus on naming and reading nouns and verbs in Parkinson's disease 353
Basi neuro anatomiche delle funzioni cognitive e del comportamento 228
Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants 182
Unilateral Extradural Motor Cortex Stimulation is Safe and Improves Parkinson's Disease at 1 Year 181
Relationships of Dietary Patterns, Foods, and Micro- and Macronutrients with Alzheimer's Disease and Late-Life Cognitive Disorders: A Systematic Review 178
Cognitive outcome 5 years after bilateral chronic stimulation of subthalamic nucleus in patients with Parkinson's disease 176
Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing 170
Sexual Behavior in Women with Bipolar Disorder 166
Extradural motor cortex stimulation improves gait, speech, and language in a patient with pure akinesia 161
Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation 156
New insights into the genetic etiology of Alzheimer's disease and related dementias 142
Oxidative Stress And Overexpression Of Manganese Superoxide Dismutase In Patients With Alzheimer's Disease. 139
Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey 139
Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry 138
Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life 136
Extradural Motor Cortex Stimulation in Parkinson's Disease: Long-Term Clinical Outcome. 135
Additive Role of a Potentially Reversible Cognitive Frailty Model and Inflammatory State on the Risk of Disability: The Italian Longitudinal Study on Aging. 134
Role of CLU, PICALM, and TNK1 Genotypes in Aging With and Without Alzheimer's Disease 134
Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention 134
Analysis of blink rate in patients with blepharospasm 130
High frequency extradural motor cortex stimulation transiently improves axial symptoms in a patient with Parkinson's disease 130
Extradural Motor Cortex Stimulation might improve episodic and working memory in patients with Parkinson’s disease 128
Contribution of Mediterranean Diet in the Prevention of Alzheimer's Disease. 125
Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides 124
APOE epsilon 2/epsilon 4 genotype a risk factor for primary progressive aphasia in women 123
Long-term outcome of subthalamic nucleus DBS in Parkinson's disease: from the advanced phase towards the late stage of the disease? 122
Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson’s disease: Need for long-term trials. 116
The potential of solanezumab and gantenerumab to prevent Alzheimerâ s disease in people with inherited mutations that cause its early onset 116
An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities 115
Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores 113
Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy 112
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (Nature Genetics, (2019), 51, 3, (414-430), 10.1038/s41588-019-0358-2) 112
Neuropsychological features of patients with Parkinson’s disease and impulse control disorders 110
Psychotropic drugs and CYP2D6 in late-life psychiatric and neurological disorders. What do we know? 109
Cognitive and behavioural changes after deep brain stimulation of the subthalamic nucleus in Parkinson’s disease 108
Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease 108
Reversible Cognitive Frailty, Dementia, and All-Cause Mortality. The Italian Longitudinal Study on Aging 107
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease 107
Disproportionate Impairment in Naming and Comprehension of Nouns with Relative Sparing of Verbs in a Patient who Survived Herpes Simplex Encephalitis 106
Accelerated Long-Term Forgetting Limited to the Recollection Component of Recognition Memory in a Temporal Lobe Epileptic Patient 105
Neuroanatomical Correlates of Category-specific Semantic Disorders: A Critical Survey 104
Genetically elevated high-density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease 104
Social Frailty in the COVID-19 Pandemic Era 104
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients 103
Selective impairment of action-verb naming and comprehension in progressive supranuclear palsy 100
Effects of deep brain stimulation of the subthalamic nucleus on patients with Parkinson's disease: a machine-learning voice analysis 97
Freezing of gait in Parkinson's disease: the paradoxical interplay between gait and cognition 94
Apolipoprotein E ε4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients 94
Italian Frontotemporal Dementia Network (FTD Group-SINDEM): sharing clinical and diagnostic procedures in Frontotemporal Dementia in Italy 93
Nutritional Intervention as a Preventive Approach for Cognitive-Related Outcomes in Cognitively Healthy Older Adults: A Systematic Review 93
Oral frailty and its determinants in older age: a systematic review 93
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease 92
Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease 91
Tau-directed approaches for the treatment of Alzheimers disease: Focus on leuco-methylthioninium 91
Early rightwards orienting of attention on simple reaction time performance in patients with left-sided neglect 90
Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging 90
TOMM40, APOE, and APOC1 in Primary Progressive Aphasia and Frontotemporal Dementia 89
Clusters of cognitive and behavioral disorders clearly distinguish primary progressive aphasia from frontal lobe dementia, and Alzheimer's disease 89
Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer's disease? 89
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders 88
Cognitive frailty: a potential target for secondary prevention of dementia 87
Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs 87
The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes 87
FOXP2, APOE, and PRNP: New Modulators in Primary Progressive Aphasia 86
Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy 86
The role of biomarkers in psychiatry 85
Early visual memory deficits: a neuropsychological marker of GBA mutations in PD? 84
The missing ApoE allele 84
Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease: a treatment-resistant depressive disorder 83
Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease 82
Alzheimer disease risk associated with APOE4 is modified by STH gene polymorphism 82
Polymorphism C in the serotonin 1 transporter gene in depression-free elderly patients with vascular dementia 81
Cognitive frailty: definitions, components, and impact on disability and mortality 81
Spinal cord stimulation may improve gait and cognition in hereditary spastic paraplegia with mental retardation: a case report 80
Genetic Associations Between Modifiable Risk Factors and Alzheimer Disease 80
The need of an extensive neuropsychological assessment for a reliable diagnosis of mild cognitive impairment in patients with Parkinson's disease 80
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial 80
ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease 79
Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease 79
Malattia di Parkinson e altri disordini del movimento 79
Corrigendum to "Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review" Neurosci. Biobehav. Rev. 95 (2018) 480-498 78
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs 78
Functional disorders after COVID-19 vaccine fuel vaccination hesitancy 78
Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study 78
Normal pressure hydrocephalus 77
Genotypes and haplotypes in the IL-1 gene cluster: Analysis of two genetically and diagnostically distinct groups of Alzheimer patients 77
Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders 76
The diagnostic accuracy of late-life depression is influenced by subjective memory complaints and educational level in an older population in Southern Italy 76
Zolpidem in Parkinson's disease 75
APOE ε2-ε4 genotype is a possible risk factor for primary progressive aphasia [6] 75
Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation 75
Botulinum Toxin Type A for the Treatment of Lower Limb Spasticity after Stroke 72
The Challenge of Antidepressant Therapeutics in Alzheimer's Disease 71
Clinical Indicators of Oral Frailty: A Domain-specific Frailty Phenotype 71
Disease-modifying therapies for tauopathies: agents in the pipeline 69
Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline 69
Social Dysfunction and Apathy: Transdiagnostic Domains in Late-Life Cognitive Disorders 67
Phytochemicals in the Treatment of Alzheimer's Disease: A Systematic Review 67
Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review 67
Totale 11.108
Categoria #
all - tutte 72.967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.967


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021582 0 0 0 0 0 49 138 60 104 131 65 35
2021/20221.095 80 73 31 71 112 51 28 151 65 53 172 208
2022/20232.086 229 235 170 227 181 258 187 145 249 72 62 71
2023/20241.315 72 362 61 61 75 124 117 51 32 46 147 167
2024/20252.690 56 54 197 105 146 106 75 133 433 277 607 501
2025/20264.834 1.260 267 748 1.198 1.150 211 0 0 0 0 0 0
Totale 15.493